FDA issues emergency recall of compounded semaglutide after concentration errors linked to overdose events
FDA issued an emergency recall of compounded semaglutide products from a single 503B outsourcing facility following reports of serious adverse events — including hospitalisations and at least two fatalities — attributed to tenfold concentration errors in compounded vials. Affected units were labelled as 1 mg/mL but contained approximately 10 mg/mL. FDA is advising patients who obtained compounded semaglutide after January 2027 to stop use immediately and contact their prescriber.
On 18 February 2027, FDA issued an emergency recall of compounded semaglutide products from a named 503B outsourcing facility following reports of serious adverse events including hospitalisations and fatalities attributed to tenfold concentration errors. Vials labelled as 1 mg/mL contained approximately 10 mg/mL of semaglutide. Patients self-administering using volume-based dosing instructions therefore received 10× the intended dose. The affected facility has been placed under a voluntary injunction and FDA inspection. The FDA safety alert ↗ identifies lot numbers and the facility name.
Clinical presentation of semaglutide overdose
Semaglutide overdose causes severe and prolonged GLP-1 receptor over-activation. Reported manifestations include severe nausea, intractable vomiting, profound hypoglycaemia (particularly in patients also taking insulin or sulfonylureas), acute pancreatitis, and cardiovascular events secondary to dehydration and electrolyte disturbance. The long half-life of semaglutide (~7 days) means that toxicity from a single overdose may persist for 1–2 weeks. There is no approved reversal agent. Management is supportive: IV fluids, antiemetics, glucose supplementation, and inpatient monitoring. Emergency clinicians should be aware that compounded formulations may not be identifiable from standard drug screening panels. See the GLP-1 receptor agonist glossary entry.
Context: compounded semaglutide and the shortage wind-down
Compounded semaglutide proliferated widely during the 2022–2026 semaglutide shortage period, with hundreds of 503A and 503B facilities producing products of variable quality. Following FDA's October 2026 declaration that the semaglutide shortage was resolved, compounded versions were required to cease by November 2026. This recall involves products manufactured or distributed after that deadline — raising questions about regulatory compliance at the implicated facility. This incident underscores the quality and safety risks inherent in compounded versions of complex peptide drugs, which require precise reconstitution and concentration verification. See also the drug compounding regulation learning module.
What patients should do
Any patient who obtained compounded semaglutide from a 503B outsourcing facility after November 2026 should: (1) stop injecting the product immediately; (2) contact their prescriber; (3) seek emergency care if they experience severe nausea, vomiting, confusion, or hypoglycaemia symptoms. Pharmacies in possession of affected lots should quarantine product and await return instructions from the recalling firm. Report adverse events via FDA MedWatch ↗. Patients needing to continue semaglutide therapy should be switched to approved Ozempic or Wegovy pens, which are now available without shortage constraints.
FAQ
How do I know if my batch is affected by this recall?
Check the lot number printed on the product label or carton against the specific lots listed in the official FDA recall notice ↗. If your lot number matches, do not use the product and contact your pharmacy or the recalling firm. You can also search the FDA Recalls database ↗ for the latest status.
What recall class is this?
FDA assigns recall classes: Class I (most serious — reasonable probability of serious adverse health consequences or death), Class II (may cause temporary or medically reversible adverse health consequences), or Class III (unlikely to cause adverse health consequences). The class is listed in the official notice ↗. For definitions see the FDA recall classification guide ↗.